• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Cannabinoid Receptors / Related Products
You are here: Product Lines > Neurobiology > Cannabinoid Receptors / Related Products
 
Toolbar - View Selection
 
 Items 1-20 of 67 Page 1 of 4 Select Page: 1 2 3 4  >>  
ALX-270-022 Revised 09-Jan-08
AEBSF . hydrochloride
Add to Clipboard
SYNONYMS 4-(2-Aminoethyl)benzenesulfonylfluoride . HCl
Pefabloc®SC
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Proteases Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-022-M050   50 mg 40.00 USD Add To Cart
ALX-270-022-M250   250 mg 145.00 USD Add To Cart
ALX-270-022-G001   1 g 360.00 USD Add To Cart
Product Specification
FORMULA: C8H10FNO2S . HCl
MW: 203.2 . 36.5
CAS NUMBER: 30827-99-7
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from moisture.

Product Description
Specific irreversible inhibitor of serine proteases including trypsin, chymotrypsin, plasmin, plasma kallikrein, and thrombin. Stable, non-toxic alternative to PMSF (Prod. No. ALX-270-184). Inhibitor of NAD(P)H oxidase. Activator of MAP kinases JNK and p38.
Product Specific Literature References
Irreversible enzyme inhibitors. 180. Irreversible inhibitors of the C'la component of complement derived from m-(phenoxypropoxy)benzamidine and phenoxyacetamide: B.R. Baker & H.J. Cory; J. Med. Chem. 14, 119 (1971) Abstract
Serine protease inhibitors block priming of monocytes for enhanced release of superoxide: P. Megyeri, et al.; Immunology 86, 629 (1995) Abstract; Full Text
Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF: M. Citron, et al.; Neuron 17, 171 (1996) Abstract
Lysis of leukemic cells by human macrophages: inhibition by 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), a serine protease inhibitor: Y. Nakabo & M.J. Pabst; J. Leukoc. Biol. 60, 328 (1996) Abstract; Full Text
Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds: V. Diatchuk, et al.; J. Biol. Chem. 272, 13292 (1997) Abstract; Full Text
4-(2-Aminoethyl)benzenesulfonyl fluoride attenuates tumor-necrosis-factor-alpha-induced blood-brain barrier opening: P. Megyeri, et al.; Eur. J. Pharmacol. 374, 207 (1999) Abstract
Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis: R. Buitrago-Rey, et al.; J. Antimicrob. Chemother. 49, 871 (2002) Abstract; Full Text
Heme oxygenase-1 gene activation by the NAD(P)H oxidase inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride via a protein kinase B, p38-dependent signaling pathway in monocytes: N. Wijayanti, et al.; J. Biol. Chem. 280, 21820 (2005) Abstract; Full Text
Inhibitory effect of 4-(2-aminoethyl)-benzenesulfonyl fluoride, a serine protease inhibitor, on PI3K inhibitor-induced CHOP expression: T. Hosoi, et al.; Eur. J. Pharmacol. 554, 8 (2007) Abstract
Further Categories Containing This Product:
Heme Oxygenase / Related Products • Cell Stress, Oxidative Stress & Redox Signalling Other Products • MAPK Pathway Activators • Fatty Acid Amide Hydrolase [FAAH] / Related Products
 
 
ALX-340-064 Revised 10-Jul-08
AM 1172
Add to Clipboard
SYNONYMS N-5Z,8Z,11Z,14Z-Eicosatetraenyl-4-hydroxy-benzamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-064-M001   1 mg 57.00 USD Add To Cart
ALX-340-064-M005   5 mg 254.00 USD Add To Cart
Product Specification
FORMULA: C27H39NO2
MW: 409.6
CAS NUMBER: 251908-92-6
PURITY: ≥98%
FORMULATION: Liquid. Solution in ethanol.
SOLUBILITY: 30mg/ml soluble in DMSO or dimethyl formamide; sparingly soluble in PBS, pH 7.2 (0.15mg/ml).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C. We do not recommend storing aqueous solutions for more than one day.

Product Description
Potent and selective inhibitor of anandamide uptake, resistant to fatty acid amide hydrolase (FAAH) hydrolysis. Metabolically stable “reversed” isomer of AM 404 (Prod. No. ALX-340-032).
Product Specific Literature References
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172: D. Fegley, et al.; PNAS 101, 8756 (2004) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION To change the solvent, evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice.
Related Products
 
 
ALX-270-239 Revised 19-Jun-08
AM 251
Add to Clipboard
SYNONYMS N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-239-M001   1 mg 29.00 USD Add To Cart
ALX-270-239-M005   5 mg 131.00 USD Add To Cart
Product Specification
FORMULA: C22H21Cl2IN4O
MW: 555.2
CAS NUMBER: 183232-66-8
PURITY: ≥98%
APPEARANCE: White to light pink solid.
SOLUBILITY: Soluble in 100% ethanol, DMSO or dimethyl formamide.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C

Product Description
Structurally related to the cannabinoid receptor (CB) antagonist SR 141716A. Binds with high affinity to cannabinoid receptor CB1 (Ki=7.49nM; 306-fold selective over CB2 receptors).
Product Specific Literature References
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors: S.J. Gatley, et al.; Life Sci. 61, PL 191 (1997) Abstract
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists: R. Lan, et al.; J. Med. Chem. 42, 769 (1999) Abstract
Inhibition of voltage-sensitive sodium channels by the cannabinoid 1 receptor antagonist AM 251 in mammalian brain: C. Liao, et al.; Basic Clin. Pharmacol. Toxicol. 94, 73 (2004) Abstract
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat: A.P. Chambers, et al.; Physiol. Behav. 82, 863 (2004) Abstract
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats: P.J. McLaughlin, et al.; Psychopharmacology (Berlin) 180, 286 (2005) Abstract
The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis: K. Matsuda, et al.; Tohoku J. Exp. Med. 207, 99 (2005) Abstract; Full Text
Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice: R.J. Rodgers, et al.; Behav. Pharmacol. 16, 405 (2005) Abstract
AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion: A.P. Chambers, et al.; Br. J. Pharmacol. 147, 109 (2006) Abstract; Full Text
 
 
ALX-270-240 Revised 05-May-08
AM 281
Add to Clipboard
SYNONYMS 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-240-M001   1 mg 25.00 USD Add To Cart
ALX-270-240-M005   5 mg 70.00 USD Add To Cart
ALX-270-240-M025   25 mg 290.00 USD Add To Cart
Product Specification
FORMULA: C21H19Cl2IN4O2
MW: 557.2
CAS NUMBER: 202463-68-1
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in methanol (1mg/ml) or DMSO (2mg/ml at RT, 50mg/ml in hot DMSO, after cooling this solution is stable over several days.)
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
IDENTITY: Identity determined by 1H-NMR.

Product Description
Analog of the cannabinoid receptor (CB) antagonist SR 141716A. Potent CB1 receptor antagonist/inverse agonist (Ki=14nM).
Product Specific Literature References
Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices: A.N. Gifford, et al.; Neurosci. Lett. 238, 84 (1997) Abstract
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo: S.J. Gatley, et al.; J. Neurochem. 70, 417 (1998) Abstract
Large receptor reserve for cannabinoid actions in the central nervous system: A. N. Gifford, et al.; J. Pharmacol. Exp. Ther. 288, 478 (1999) Abstract
Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats: N.A. Werner, et al.; Brain Res. 967, 290 (2003) Abstract
Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats: Y. Kadoi, et al.; Br. J. Anaesth. 94, 563 (2005) Abstract
Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats: Y. Kadoi, et al.; Crit. Care Med. 33, 2629 (2005) Abstract
 
 
ALX-340-032 Revised 04-Jul-08
AM 404
Add to Clipboard
SYNONYMS N-(4-Hydroxyphenyl)-5Z,8Z,11Z-eicosatetraenamide
N-(4-Hydroxyphenyl)arachidonoylamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide & Anandamide Analogs
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-032-M005   5 mg 40.00 USD Add To Cart
Product Specification
FORMULA: C26H37NO2
MW: 395.6
CAS NUMBER: 198022-70-7
PURITY: ≥98%
APPEARANCE: Waxy solid.
SOLUBILITY: Soluble in DMSO or 100% ethanol (>25mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for up to one year after receipt when stored at -20°C. Solutions are stable for up to 3 months when stored at -20°C under an inert atmosphere of nitrogen or argon.
HANDLING: Protect from air.

Product Description
Analog of anandamide (Prod. No. ALX-340-029). Potentiates the activity of endogenous anandamide by blocking its re-uptake into presynaptic membranes. Activates TRPV1 (EC50=0.04µM) at concentrations lower than those required to inhibit anandamide transport into the cell (neuronal (C6 glioma cells): IC50=10µM; non-neuronal (rat RBL-2H3 cells): IC50=11µM). Low affinity to FAAH (IC50=5.9µM), to CB1 receptor (IC50=1.76µM) and to CB2 receptor (IC50>1µM).
Product Specific Literature References
Potentiation of anandamide hypotension by the transport inhibitor, AM404: A. Calignano, et al.; Eur. J. Pharmacol. 337, R1 (1997) Abstract
Functional role of high-affinity anandamide transport, as revealed by selective inhibition: M. Beltramo, et al.; Science 277, 1094 (1997) Abstract
Structural determinants for recognition and translocation by the anandamide transporter: D. Piomelli, et al.; PNAS 96, 5802 (1999) Abstract
The anandamide transport inhibitor AM404 activates vanilloid receptors: P.M. Zygmunt, et al.; Eur. J. Pharmacol. 396, 39 (2000) Abstract
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis, et al.; FEBS Lett. 483, 52 (2000) Abstract
Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function: E. Fernandez-Espejo, et al.; Neuropsychopharmacology 29, 1134 (2004) Abstract
Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors: B.G. Kelley and S.A. Thayer; Eur. J. Pharmacol. 496, 33 (2004) Abstract
AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain: B. Costa, et al.; Br. J. Pharmacol. 148, 1022 (2006) Abstract
Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]: G. La Rana, et al.; J. Pharmacol. Exp. Ther. 317, 1365 (2006) Abstract
Further Categories Containing This Product:
NOS Inhibitors (NOS Induction & Enzyme Activity) • Anandamide Uptake Inhibitors • TRPV1 Agonists and Antagonists / Related Products
 
 
ALX-270-241 Revised 03-Mar-05
AM 630
Add to Clipboard
SYNONYMS (6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl)(4-methoxyphenyl)methanone
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-241-M001   1 mg 20.00 USD Add To Cart
ALX-270-241-M005   5 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C23H25IN2O3
MW: 504.4
CAS NUMBER: 164178-33-0
PURITY: ≥98%
APPEARANCE: Off-white solid.
SOLUBILITY: Soluble in DMSO or dimethyl formamide.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from light and oxygen.

Product Description
Competitive CB1 receptor antagonist in guinea-pig brain. Shows also agonist properties. CB2 antagonist/inverse agonist (Ki=31.2nM; 165-fold selective over CB1 receptors).
Product Specific Literature References
AM630, a competitive cannabinoid receptor antagonist: R. Pertwee, et al.; Life Sci. 56, 1949 (1995) Abstract
AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain: K. Hosohata, et al.; Life Sci. 61, PL115 (1997) Abstract
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain: Y. Hosohata, et al.; Eur. J. Pharmacol. 321, R1 (1997) Abstract
AM630 is an inverse agonist at the human cannabinoid CB1 receptor: R.S. Landsman, et al.; Life Sci. 62, PL109 (1998) Abstract
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630: R.A. Ross, et al.; Br. J. Pharmacol. 126, 665 (1999) Abstract
Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats: N.A. Werner, et al.; Brain Res. 967, 290 (2003) Abstract
 
 
ALX-550-383 Revised 11-Apr-07
AM 1241
Add to Clipboard
SYNONYMS (2-Iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-383-M001   1 mg 40.00 USD Add To Cart
ALX-550-383-M005   5 mg 110.00 USD Add To Cart
Product Specification
FORMULA: C22H22N3O3I
MW: 503.3
PURITY: ≥97% (TLC)
APPEARANCE: Yellow powder.
SOLUBILITY: Soluble in DMSO, dimethyl formamide, 100% ethanol or methanol; insoluble in water.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Unstable in 1M NaOH; slightly unstable in 1M HCl.
HANDLING: Packaged under inert gas. Protect from light.

Product Description
Potent and selective CB2 receptor agonist (Ki=3.4nM (mouse), Ki=280nM (rat) also in vivo.
Product Specific Literature References
CB2 cannabinoid receptor-mediated peripheral antinociception: T.P. Malan, Jr., et al.; Pain 93, 239 (2001) Abstract
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS: M.M. Ibrahim, et al.; PNAS 100, 10529 (2003) Abstract; Full Text
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation: A.G. Nackley, et al.; Neuroscience 119, 747 (2003) Abstract
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors: A. Quartilho, et al.; Anesthesiology 99, 955 (2003) Abstract
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin: A.G. Hohmann, et al.; J. Pharmacol. Exp. Ther. 308, 446 (2004) Abstract
In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?: B.B. Yao, et al.; Br. J. Pharmacol. 149, 145 (2006) Abstract
 
 
ALX-340-029 Revised 08-Jul-08
Anandamide
Add to Clipboard
SYNONYMS AEA
N-Arachidonoylethanolamine
(all-Z)-N-(2-Hydroxyethyl)-5,8,11,14-eicosatetraenamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide & Anandamide Analogs
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-029-M005   5 mg 51.00 USD Add To Cart
Product Specification
FORMULA: C22H37NO2
MW: 347.5
CAS NUMBER: 94421-68-8
MERCK INDEX: 14: 624
RTECS: JX3842500
CONCENTRATION: 50mg/ml 
PURITY: ≥98%
FORMULATION: Liquid. Solution in ethanol.
SOLUBILITY: 10mg/ml soluble in DMSO or dimethyl formamide.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 6 months in other organic solvents when stored at -20°C.
HANDLING: Protect from light and oxygen.

Product Description
Endogenous [1] ligand for the CB1 receptor (CB1: Ki=52nm; CB2: Ki=1930nm [2]) and TRPV1 (Ki=5.78µM [3,4]). Inhibits NF-κB activation through direct binding to IKKβ [5] and induces apoptosis independently of cannabinoid or vanilloid receptors [6]. Activates the MAP kinase (MAPK/ERK) signalling pathway [7].
Product Specific Literature References
[1] Isolation and structure of a brain constituent that binds to the cannabinoid receptor: W.A. Devane, et al.; Science 258, 1946 (1992) Abstract
[2] Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability: S. Lin, et al.; J. Med. Chem. 41, 5353 (1998) Abstract
[3] Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide: P.M. Zygmunt, et al.; Nature 400, 452 (1999) Abstract
[4] Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens: R.A. Ross, et al.; Br. J. Pharmacol. 132, 631 (2001) Abstract
[5] Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway: R. Sancho, et al.; Mol. Pharmacol. 63, 429 (2003) Abstract
[6] Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts: K.P. Sarker, et al.; Cell Mol. Life Sci. 60, 1200 (2003) Abstract
[7] The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide: M. Wartmann, et al.; FEBS Lett. 359, 133 (1995) Abstract
Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid: C.J. Hillard & W.B. Campbell; J. Lipid Res. 38, 2383 (1997), (Review) Abstract
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation: L. De Petrocellis, et al.; PNAS 95, 8375 (1998) Abstract
Cannabinoid receptors and their endogenous agonist, anandamide: J. Axelrod & C.C. Felder; Neurochem. Res. 23, 575 (1998), (Review) Abstract
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action: V. Di Marzo, et al.; TINS 21, 521 (1998), (Review) Abstract
Endocannabinoids: a new class of vasoactive substances: M.D. Randall & D.A. Kendall; TIPS 19, 55 (1998), (Review) Abstract
Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments: V. Di Marzo, et al.; Lipids 34, S319 (1999), (Review) Abstract
Anandamide: a candidate neurotransmitter heads for the big leagues: D.W. Self; Nat. Neurosci. 2, 303 (1999), (Review) Abstract
New perspectives on enigmatic vanilloid receptors: A. Szallasi & V. Di Marzo; TINS 23, 491 (2000), (Review) Abstract
Anandamide: some like it hot: V. Di Marzo, et al.; TIPS 22, 346 (2001), (Review) Abstract
Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes: J. Joseph, et al.; Cancer Immunol. Immunother. 53, 723 (2004) Abstract
Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways: V.A. Movsesyan, et al.; Cell Death Differ. 11, 1121 (2004) Abstract
Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1: E. Contassot, et al.; J. Neuropathol. Exp. Neurol. 63, 956 (2004) Abstract
Preferred conformations of endogenous cannabinoid ligand anandamide: J.Z. Chen, et al.; Life Sci. 76, 2053 (2005) Abstract
The cardiovascular actions of anandamide: more targets?: M.D. Randall; Br. J. Pharmacol. 145, 565 (2005) Abstract; Full Text
Accumulation of anandamide: Evidence for cellular diversity: C.J. Hillard and A. Jarrahian; Neuropharmacology 48, 1072 (2005) Abstract
Anandamide as an intracellular messenger regulating ion channel activity: M. van der Stelt and V. Di Marzo; Prostaglandins Other Lipid Mediat. 77, 111 (2005)